Literature DB >> 8643644

Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines.

F F Casanueva1, F R Perez, X Casabiell, J P Camiña, R Z Cai, A V Schally.   

Abstract

Bombesin (BN) acts as an autocrine mitogen in various human cancers. Several pseudononapeptide BN-(6-14) analogs with a reduced peptide bond between positions 13 and 14 have been shown to suppress the mitogenic activity of BN or gastrin-releasing peptide (GRP) when assessed by radioreceptor or proliferation assays and may have significant clinical applications. The search for potent and safe BN antagonists requires the evaluation of a large series of analogs in radioreceptor and proliferation assays. In this paper, we report that the ability of BN analogs to inhibit BN-induced calcium transients in Swiss 3T3 cells shows a high correlation with their inhibitory potency as evaluated by classical proliferation tests. The assay of calcium transients allows a rapid characterization of new BN analogs (in terms of minutes rather than days) and can be adapted as a labor and cost-effective screening step in the selection of potentially relevant BN antagonists for further characterization in cell proliferation systems. We also observed that results from the assay of calcium transients in Swiss 3T3 cells can be correlated with the results of the proliferative response in HT-29 cells, a cell line that does not seem to use the same early transmembrane ionic signal system. This result suggests that the calcium pathway is not mandatory for triggering cell division by the BN receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643644      PMCID: PMC39951          DOI: 10.1073/pnas.93.4.1406

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.

Authors:  T Yano; J Pinski; K Groot; A V Schally
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.

Authors:  R Z Cai; H Reile; P Armatis; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

3.  Bombesin suppresses feeding in rats.

Authors:  J Gibbs; D J Fauser; E A Rowe; B J Rolls; E T Rolls; S P Maddison
Journal:  Nature       Date:  1979-11-08       Impact factor: 49.962

4.  Differential effects of carboxy-terminal sequence deletions on platelet-derived growth factor receptor signaling activities and interactions with cellular substrates.

Authors:  K Seedorf; B Millauer; G Kostka; J Schlessinger; A Ullrich
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

5.  Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi.

Authors:  R Z Cai; S Radulovic; J Pinski; A Nagy; T W Redding; D B Olsen; A V Schally
Journal:  Peptides       Date:  1992 Mar-Apr       Impact factor: 3.750

6.  Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.

Authors:  Y Qin; G Halmos; R Z Cai; B Szoke; T Ertl; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.

Authors:  Y Shirahige; R Z Cai; K Szepeshazi; G Halmos; J Pinski; K Groot; A V Schally
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529

8.  Oleic acid blocks EGF-induced [Ca2+]i release without altering cellular metabolism in fibroblast EGFR T17.

Authors:  J L Zugaza; X A Casabiell; L Bokser; F F Casanueva
Journal:  Biochem Biophys Res Commun       Date:  1995-02-06       Impact factor: 3.575

9.  Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.

Authors:  K Szepeshazi; A V Schally; G Halmos; K Groot; S Radulovic
Journal:  J Natl Cancer Inst       Date:  1992-12-16       Impact factor: 13.506

10.  Pretreatment with oleic acid accelerates the entrance into the mitotic cycle of EGF-stimulated fibroblasts.

Authors:  J L Zugaza; X A Casabiell; L Bokser; A Eiras; A Beiras; F F Casanueva
Journal:  Exp Cell Res       Date:  1995-07       Impact factor: 3.905

View more
  9 in total

1.  Bombesin enhances TGF-beta growth inhibitory effect through apoptosis induction in intestinal epithelial cells.

Authors:  Xianghua Liu; Junmei Zhao; Fazhi Li; Yan-shi Guo; Mark R Hellmich; Courtney M Townsend; Yanna Cao; Tien C Ko
Journal:  Regul Pept       Date:  2009-07-23

2.  Gastrin-releasing peptide is a growth factor for human neuroblastomas.

Authors:  Sunghoon Kim; Wanqin Hu; David R Kelly; Mark R Hellmich; B Mark Evers; Dai H Chung
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

3.  The role of gastrin-releasing peptide on conditioned fear: differential cortical and amygdaloid responses in the rat.

Authors:  Christine Mountney; Victoria Sillberg; Pam Kent; Hymie Anisman; Zul Merali
Journal:  Psychopharmacology (Berl)       Date:  2006-10-11       Impact factor: 4.530

4.  A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.

Authors:  K Szepeshazi; A V Schally; G Halmos; N Lamharzi; K Groot; J E Horvath
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

Authors:  G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

6.  Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.

Authors:  Ferenc G Rick; Stefan Buchholz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Elmar Aigner; Roberto Perez; Stephan Seitz; Norman L Block; Florian Hohla
Journal:  Cell Cycle       Date:  2012-07-01       Impact factor: 4.534

7.  Effects of gastrin-releasing peptide agonist and antagonist administered to the basolateral nucleus of the amygdala on conditioned fear in the rat.

Authors:  Christine Mountney; Hymie Anisman; Zul Merali
Journal:  Psychopharmacology (Berl)       Date:  2008-06-18       Impact factor: 4.530

Review 8.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Authors:  Florian Hohla; Thomas Winder; Richard Greil; Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

9.  Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Authors:  Bogdan Mitran; Zohreh Varasteh; Ayman Abouzayed; Sara S Rinne; Emmi Puuvuori; Maria De Rosa; Mats Larhed; Vladimir Tolmachev; Anna Orlova; Ulrika Rosenström
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.